Switch theme
Sign up to access all valuation multiples
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company’s focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
2016
129
LTM Revenue $34.1M
Last FY EBITDA -$90.2M
-$64.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Repare Therapeutics has a last 12-month revenue (LTM) of $34.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Repare Therapeutics achieved revenue of $53.5M and an EBITDA of -$90.2M.
Repare Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Repare Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $34.1M | XXX | $53.5M | XXX | XXX | XXX |
| Gross Profit | $34.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$90.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -169% | XXX | XXX | XXX |
| EBIT | -$95.2M | XXX | -$92.1M | XXX | XXX | XXX |
| EBIT Margin | -279% | XXX | -172% | XXX | XXX | XXX |
| Net Profit | -$88.4M | XXX | -$84.7M | XXX | XXX | XXX |
| Net Margin | -259% | XXX | -158% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Repare Therapeutics's stock price is $1.
Repare Therapeutics has current market cap of $58.8M, and EV of -$64.1M.
See Repare Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$64.1M | $58.8M | XXX | XXX | XXX | XXX | $-2.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Repare Therapeutics has market cap of $58.8M and EV of -$64.1M.
Repare Therapeutics's trades at -1.2x EV/Revenue multiple, and 0.7x EV/EBITDA.
Equity research analysts estimate Repare Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Repare Therapeutics has a P/E ratio of -0.7x.
See valuation multiples for Repare Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $58.8M | XXX | $58.8M | XXX | XXX | XXX |
| EV (current) | -$64.1M | XXX | -$64.1M | XXX | XXX | XXX |
| EV/Revenue | -1.9x | XXX | -1.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBIT | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/Gross Profit | -1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRepare Therapeutics's last 12 month revenue growth is -76%
Repare Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.1M for the same period.
Repare Therapeutics's rule of 40 is -300% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Repare Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Repare Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -76% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -169% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -300% | XXX | -245% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 217% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 272% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Repare Therapeutics acquired XXX companies to date.
Last acquisition by Repare Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Repare Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Repare Therapeutics founded? | Repare Therapeutics was founded in 2016. |
| Where is Repare Therapeutics headquartered? | Repare Therapeutics is headquartered in United States of America. |
| How many employees does Repare Therapeutics have? | As of today, Repare Therapeutics has 129 employees. |
| Who is the CEO of Repare Therapeutics? | Repare Therapeutics's CEO is Mr. Steve Forte. |
| Is Repare Therapeutics publicy listed? | Yes, Repare Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Repare Therapeutics? | Repare Therapeutics trades under RPTX ticker. |
| When did Repare Therapeutics go public? | Repare Therapeutics went public in 2020. |
| Who are competitors of Repare Therapeutics? | Similar companies to Repare Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Repare Therapeutics? | Repare Therapeutics's current market cap is $58.8M |
| What is the current revenue of Repare Therapeutics? | Repare Therapeutics's last 12 months revenue is $34.1M. |
| What is the current revenue growth of Repare Therapeutics? | Repare Therapeutics revenue growth (NTM/LTM) is -76%. |
| What is the current EV/Revenue multiple of Repare Therapeutics? | Current revenue multiple of Repare Therapeutics is -1.9x. |
| Is Repare Therapeutics profitable? | Yes, Repare Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
